Hydrocortisone and Deflazacort Induce Different Effects on Vitamin D Receptor Level Increase Produced by 1,25-Dihydroxyvitamin D3 in Rat Osteoblast-like UMR-106 Cells

Journal of Rheumatology

Volumn 31, Issue 1, 2004, Pages 167-172

  Guerrero, Rosa ^a,b   La Piedra, Concepción De ^a,b   Teixeiro, Emma ^a,c   Bragado, Rafael ^a,c   Traba, Maria Luisa ^a,b,d  

^a Fundacion Jimenez Diazy   (Spain)

^b Biochemistry Laboratory   (Spain)

^c Immunology Section   (India)

^d Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

1,25 Dihydroxyvitamin D; Cortisol; Deflazacort; Vitamin D receptor; Vitamin D receptor mRNA

Indexed keywords

CALCITRIOL; DEFLAZACORT; HYDROCORTISONE; MESSENGER RNA; VITAMIN D RECEPTOR;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; BONE METABOLISM; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISSOCIATION CONSTANT; DRUG ACTIVITY; INCUBATION TIME; NONHUMAN; NORTHERN BLOTTING; OSTEOBLAST; OSTEOSARCOMA; PRIORITY JOURNAL; RAT; RNA ANALYSIS; STATISTICAL SIGNIFICANCE; VITAMIN D METABOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CALCITRIOL; CALCIUM CHANNEL AGONISTS; CELL LINE; HYDROCORTISONE; OSTEOBLASTS; PREGNENEDIONES; RATS; RECEPTORS, CALCITRIOL; RNA, MESSENGER; TRITIUM;

EID: 0347949595     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Darwish HM, DeLuca HF. Recent advances in the molecular biology of vitamin D action. Prog Nucleic Acid Res Mol Biol 1996;53:321-44.
2. Pike JW. Vitamin D3 receptors: Structure and function in transcription. Annu Rev Nutr 1991;11:189-216.
3. Mahonen A, Pirskanen A, Mäenpää PH. Homologous and heterologous regulation of 1,25-dihydroxyvitamin D3 receptor mRNA levels in human osteosarcoma cells. Biochim Biophys Acta 1991;1088:111-8.
4. Manolagas SC, Anderson DC, Lumb GA. Glucocorticoids regulate the concentration of 1,25-dihydroxy vitamin D receptor in bone. Nature 1979;227:314-5.
5. Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 1999;14:1061-6.
6. McKenzie R, Reynolds JC, O'Fallon A, et al. Decreased bone mineral density during low dose glucocorticoid administration in a randomized, placebo controlled trial. J Rheumatol 2000;27:2222-6.
7. Scudeletti M, Castagneta L, Imbimbo B, Puppo F, Pierre I, Indiveri F. New glucocorticoids. Mechanism of immunological activity at the cellular level in the clinical setting. Ann NY Acad Sci 1990;595:368-82.
8. Markham A, Bryson HM. Deflazacort. A review of its pharmacological properties and therapeutic efficacy. Drugs 1995;50:317-33.
9. Genari C, Imbimbo B. Effects of prednisone and deflazacort on vertebral bone mass. Calcif Tissue Int 1985;37:592-3.
10. Ferraris JR, Pasqualini T, Legal S, et al. Effect of deflazacort versus methylprednisone on growth, body composition, lipid profile, and bone mass after renal transplantation. The Deflazacort Study group. Pediatr Nephrol 2000;14:682-8.
11. Canalis E, Avioli L. Effects of deflazacort on aspects of bone formation in cultures of intact calvariae and osteoblast-enriched cells. J Bone Miner Res 1992;7:1085-92.
12. Pereira RC, Durant D, Canalis E. Transcriptional regulation of connective tissue growth factor by cortisol in osteoblasts. Am J Physiol Endocrinol Metab 2000;279:E570-6.
13. Walsh CA, Birch MA, Fraser WD, et al. Expression and secretion of parathyroid hormone-related protein by human bone-derived cells in vitro: Effects of glucocorticoids. J Bone Miner Res 1995;10:17-25.
14. Borcsok I, Schairer HU, Sommer U, et al. Glucocorticoids regulate the expression of the human osteoblastic endothelium A receptor gene. J Exp Med 1998;188:1563-73.
15. Van Leeuwen JPTM, Birkenhäger JC, Vink-van Wijngaarden T, Van den Bemd GJCM, Pols HAP. Regulation of 1,25-dihydroxyvitamin D receptor gene expression by parathyroid hormone and cAMP-agonists. Biochem Biophys Res Commun 1992;185:881-6.
16. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
17. Chen TL, Hauschka PV, Feldman D. Dexamethasone increases 1,25-dihydroxyvitamin D receptor levels and augments bioresponses in rat osteoblast-like cells. Endocrinology 1986;118:1119-26.
18. Yang-Yeng HS, Chambard JC, Sun YL, et al. Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 1990;62:1205-15.
19. Hirst M, Feldman D. Glucocorticoid regulation of 1,25-dihydroxyvitamin D receptors: divergent effects on mouse and rat intestine. Endocrinology 1982;111:1400-2.
20. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: Pathogenesis and management. Ann Intern Med 1990;112:352-64.
21. Nielsen HK. Circadian changes in osteoblastic activity assessed by serum osteocalcin. Physiological and methodological aspects. Dan Med Bull 1994;41:216-27.
22. Feldman D, McCain TA, Hirst MA, Chen TL, Colston KW. Characterization of a cytoplasmic receptor-like binder for 1 alpha,25 dihydroxycholecalciferol in rat intestinal mucosa. J Biol Chem 1979;254:10378-84.
23. Komm BS, Terpening CM, Benz DJ, et al. Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science 1988;241:81-4.
24. Issa LL, Leong GM, Barry JB, Sutherland RL, Eisman JA. Glucocorticoid receptor-interacting protein-1 and receptor-associated coactivator-3 differentially interact with the vitamin D receptor (VDR) and regulate VDR-retinoid X receptor transcriptional cross-talk. Endocrinology 2001;142:1606-15.